Back to top
more

Curis (CRIS)

(Delayed Data from NSDQ)

$1.72 USD

1.72
56,510

+0.05 (2.69%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $1.72 +0.01 (0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (100 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Curis (CRIS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Curis (CRIS) delivered earnings and revenue surprises of -15.38% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of -40.66% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is the Options Market Predicting a Spike in Curis (CRIS) Stock?

by Zacks Equity Research

Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.

Zacks Equity Research

Curis (CRIS) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is the Options Market Predicting a Spike in Curis (CRIS) Stock?

by Zacks Equity Research

Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.

Zacks Equity Research

Here's Why Curis (CRIS) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

Curis (CRIS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

Down 23.2% in 4 Weeks, Here's Why Curis (CRIS) Looks Ripe for a Turnaround

by Zacks Equity Research

Curis (CRIS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Curis (CRIS) delivered earnings and revenue surprises of 7.69% and 14.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Curis (CRIS) Q3 Earnings Expected to Decline

by Zacks Equity Research

Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Curis (CRIS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Curis (CRIS) delivered earnings and revenue surprises of -9.09% and -1.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Curis (CRIS) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

New Strong Sell Stocks for May 20th

by Zacks Equity Research

AXDX, CRIS, FSTR, GO, and PRLB have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2021

Zacks Equity Research

Do Options Traders Know Something About Curis (CRIS) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.

Zacks Equity Research

Will Curis (CRIS) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Curis (CRIS) Surges: Stock Moves 5% Higher

by Zacks Equity Research

Curis (CRIS) saw a big move last session, as its shares jumped 5% on the day, amid huge volumes.

Zacks Equity Research

Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News

by Zacks Equity Research

Data readouts at ASH take centerstage in the biotech sector as Fate (FATE) and CRISPR (CRSP) among others provide key updates.

Zacks Equity Research

Curis (CRIS) Skyrockets on Promising Phase I Pipeline Updates

by Zacks Equity Research

Curis' (CRIS) hematologic malignancy candidate, CA-4948, shows promising activity in early-stage studies evaluating it in patients with either acute myeloid leukemia or non-Hodgkin's lymphoma. Stock up 350%.

Zacks Equity Research

Has Curis (CRIS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (CRIS) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Is Curis (CRIS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (CRIS) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Aduro BioTech (ADRO) Looks Good: Stock Adds 7.7% in Session

by Zacks Equity Research

Aduro BioTech (ADRO) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Nitish Marwah headshot

New Strong Buy Stocks for December 13th

by Nitish Marwah

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Zacks Equity Research

Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Curis (CRIS) delivered earnings and revenue surprises of 29.03% and 19.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Curis (CRIS) Q3 Earnings Preview: Here's What to Look Out For

by Zacks Equity Research

Curis (CRIS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is a Beat in Store for Vertex (VRTX) This Earnings Season?

by Zacks Equity Research

On Vertex' (VRTX) third-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.

Zacks Equity Research

Curis (CRIS) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Curis, Inc. (CRIS).